Brain Scans Show Effects of Psilocybin, LSD and Ayahuasca on Neural Connections

Researchers have conducted an analysis of hundreds of brain scans to investigate the impact of psychedelic substances on brain connectivity. The study focused on psilocybin, LSD and ayahuasca. These substances were administered to participants in controlled settings, with scans capturing brain activity before, during and after use.

The scans revealed alterations in connections between key brain regions, including the default mode network and sensory areas. Functional magnetic resonance imaging (fMRI) was used to measure these changes. The research involved data from multiple prior studies.

in the included studies were healthy adults aged 18 to 65.

Scans were taken at baseline, peak effects and post-administration periods up to 24 hours later. Key findings indicated reduced connectivity within the default mode network, which is associated with self-referential thinking, and increased connectivity between this network and other regions like the visual cortex.

These changes persisted in some cases for up to one month after a single dose. The study highlights potential therapeutic implications for conditions such as depression and anxiety, where similar connectivity disruptions occur.

However, researchers noted that long-term effects require further investigation through larger trials. No adverse events were reported in the scanned participants during the study periods.

like psilocybin and LSD have been studied since the mid-20th century, with renewed interest following designations as breakthrough therapies for treatment-resistant depression.

Ayahuasca, used traditionally in South American indigenous ceremonies, has been the subject of clinical trials in Brazil and the United States since the 1990s. This meta-analysis builds on that foundation by pooling neuroimaging data. Affected groups include patients with mental health disorders, as altered connectivity may inform new treatments.

Regulatory bodies are reviewing psychedelic-assisted therapies. Researchers plan to expand the dataset to include scans from diverse populations and compare effects with non-psychedelic interventions.